YD Bio Ltd (YDES) Form 424B3 — Aug 31, 2026
YD Bio (Nasdaq: YDES) filed a 424B3 prospectus supplement registering 58,571,199 ordinary shares for selling shareholders plus 11,436,270 public-warrant shares and 3,136,056 private-warrant shares, and incorporating its unaudited H1 2026 results from a Form 6-K. First-half revenue jumped 315% to $846,501 from $204,007, and the company swung to net income of $6.7 million ($0.09 EPS) — but the entire profit came from a $9.85 million non-cash gain on warrant liabilities; excluding it, the operational net loss widened 64% to $3.1 million.
Key figures
- Eps
- 0.09
- Revenue
- 846501
- Net Income
- 6700497
- Revenue Yoy
- 315%
- Cash Position
- 2662004
- Shares Outstanding
- 70842844
- Gross Profit
- 268230
- Planned2026 Capex
- $9M-$10M
- Pipe Proceeds Aug2025
- $13.2 million at $8.00 per share
- Warrant Exercise Price
- 11.5
- Warrant Fair Value Gain
- 9846532
- Last Reported Sale Price
- 4.8
- Yc Biotech Service Revenue
- 66642
- Fetroja Single Order Revenue
- 327060
- Planned2026 Operating Spend
- $2.4M-$2.7M
- Public Warrants Outstanding
- 11436270
- Warrant Liabilities Fair Value
- 4517421
- Fetroja Order Percent Of Revenue
- 39%
- Ssmc Acquisition Consideration
- approximately US$26.87 million (NT$839,832,000)
- Selling Shareholder Shares Registered
- 58571199
- Private Placement Warrants Outstanding
- 3136056
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.